1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Wuhan Keqian Biology Co. Ltd. Class A

Wuhan Keqian Biology Co. Ltd. Class A

SSSE:688526
11.78
CNY
-0.24
(-2.00%)
5.64BMarket Cap
Oct 31Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.09
1.76
2.04
1.4
2.18
2.38
2.15
2.28
2.02
2.04
- -
Basic EPS, GAAP
0.52
0.89
1.08
0.67
1.16
1.23
0.88
0.85
0.82
0.9
- -
Free Cash Flow per Basic Share
0.54
0.58
0.89
0.05
0.75
0.34
0.69
0.93
0.61
0.74
- -
Dividend per Share
0.08
0.13
0.34
0.24
- -
0.29
0.2
0.21
0.44
0.43
- -
Book Value per Share
5.5
8.97
2.43
3.11
5.82
6.78
7.5
8.23
8.45
9.09
8.65
Tangible Book Value per Share
5.25
8.57
2.34
3.02
5.71
6.66
7.37
8.09
8.32
8.95
8.51
Basic Weighted Avg Shares
358
360
360
362
386
464
465
466
466
465
464
Sales/Revenue/Turnover
390
633
735
508
843
1,103
1,001
1,064
942
950
- -
Operating Margin (%)
53.55
58.04
58.28
49.87
59.06
54.37
42.55
45.07
38.98
40.88
- -
Depreciation Expense
19
23
35
37
37
63
98
114
109
113
- -
Net Income, GAAP
186
320
389
243
448
571
410
396
382
419
- -
Effective Tax Rate (%)
13.73
14.89
13.92
12.81
13.83
13.55
12.31
13.55
12.93
13.42
- -
Profit Margin (%)
47.68
50.62
52.9
47.81
53.11
51.74
40.9
37.21
40.59
44.09
- -
Working Capital
242
395
584
645
2,107
1,269
1,937
1,808
2,010
2,470
2,639
LT Debt
- -
- -
- -
- -
- -
- -
147
6
6
5
5
Total Equity
413
673
876
1,119
2,709
3,154
3,499
3,838
3,943
4,239
4,031
Return on Invested Capital (%)
- -
55.94
45.02
22.7
23.12
18.93
11.63
10.11
9.62
10.34
- -
Return on Capital (%)
- -
58.15
50.12
23.15
23.06
19.08
11.83
10.2
9.59
10.22
- -
Return on Common Equity (%)
- -
59
50.21
24.32
23.4
19.47
12.32
10.8
9.83
10.24
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
1
2
LT Borrowings
- -
- -
- -
LT Finance Leases
5
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
466
466
466
Market Capitalization
7,113
6,768
5,640

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,927
3,110
3,026
Cash, Cash Equivalents & STI
1,719
1,880
1,847
Accounts Receivable, Net
285
320
276
Inventories
144
136
146
Total Current Liabilities
457
419
387
Payables & Accruals
- -
- -
- -
ST Debt
2
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
9.46%
7.51%
Free Cash Flow
- -
16.12%
20.62%
Net Income, GAAP
- -
0.39%
9.51%
Sales/Revenue/Turnover
- -
3.44%
0.83%
Total Cash Common Dividend
- -
7,412.4%
-2.49%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
205
196
265
276
942
2025
245
242
- -
212
950
2026
228
146
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.18
0.14
0.23
0.26
0.82
2025
0.23
0.24
- -
0.17
0.9
2026
0.17
0.08
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.43
- -
- -
0.44
2025
- -
- -
- -
- -
0.43
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mu Lin Chen
Full Time Employees
950
Sector
Health technology
Industry
Biotechnology
Address
No. 419, Gaoxin 2nd Road Wuhan HB China 430073
IPO Date
Sep 22, 2020
Website
kqbio.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Wuhan Keqian Biology Co.,Ltd (688526.SS) is a China-based biotechnology company engaged in the research, development, production, sales and animal epidemic prevention technical services of veterinary biological products. The company offers a comprehensive portfolio of vaccines for swine including non-compulsory immunization products targeting diseases such as streptococcus and other key pathogens; poultry vaccines addressing Newcastle disease and related viral threats; pet vaccines comprising feline triple combinations and other companion animal immunizations; as well as diagnostic reagents for animal disease detection and monitoring. It primarily serves large-scale farming operations, intensification hoggeries and farming group companies within the domestic Chinese market, with operations centered in Wuhan. Founded in 2001 and headquartered at No. 419, Gaoxin 2nd Road in the East Lake High-tech Development Zone, Wuhan, China, the company maintains GMP-approved facilities for vaccine production and boasts a scientific team exceeding 200 personnel including academicians and professors. In recent developments, Wuhan Keqian Biology reported robust financial growth in its 2025 semi-annual results with operating revenue up 21.67% year-over-year to 487 million yuan and net profit attributable to the parent surging 44.09% to 220 million yuan, driven by improved market conditions, higher vaccine batch releases and sales expansion particularly in pet vaccines. The company continues to prioritize new product development amid stabilizing animal health demand, with strategic focus on pet and companion animal segments alongside ongoing R&D investments exceeding RMB 50 million annually to enhance its swine and poultry portfolios; it maintains key technical collaborations with institutions like Huazhong Agricultural University for advanced vaccine innovations.